Literature DB >> 26282639

Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls.

Patrick G Gavin1, Nan Song1, S Rim Kim1, Katherine L Pogue-Geile1, Soonmyung Paik2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26282639      PMCID： PMC4816211          DOI： 10.1200/JCO.2015.61.9650

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.

Authors:  Richard Simon; Michael D Radmacher; Kevin Dobbin; Lisa M McShane
Journal:  J Natl Cancer Inst       Date:  2003-01-01       Impact factor: 13.506

2.  Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Authors:  Edith A Perez; E Aubrey Thompson; Karla V Ballman; S Keith Anderson; Yan W Asmann; Krishna R Kalari; Jeanette E Eckel-Passow; Amylou C Dueck; Kathleen S Tenner; Jin Jen; Jian-Bing Fan; Xochiquetzal J Geiger; Ann E McCullough; Beiyun Chen; Robert B Jenkins; George W Sledge; Eric P Winer; Julie R Gralow; Monica M Reinholz
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

3.  Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Authors:  Katherine L Pogue-Geile; Chungyeul Kim; Jong-Hyeon Jeong; Noriko Tanaka; Hanna Bandos; Patrick G Gavin; Debora Fumagalli; Lynn C Goldstein; Nour Sneige; Eike Burandt; Yusuke Taniyama; Olga L Bohn; Ahwon Lee; Seung-Il Kim; Megan L Reilly; Matthew Y Remillard; Nicole L Blackmon; Seong-Rim Kim; Zachary D Horne; Priya Rastogi; Louis Fehrenbacher; Edward H Romond; Sandra M Swain; Eleftherios P Mamounas; D Lawrence Wickerham; Charles E Geyer; Joseph P Costantino; Norman Wolmark; Soonmyung Paik
Journal:  J Natl Cancer Inst       Date:  2013-11-21       Impact factor: 13.506
  3 in total
  2 in total

Review 1.  Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.

Authors:  Martina Di Modica; Elda Tagliabue; Tiziana Triulzi
Journal:  Dis Markers       Date:  2017-12-18       Impact factor: 3.434

2.  Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy.

Authors:  Lun Li; Min Chen; Shuyue Zheng; Hanlu Li; Weiru Chi; Bingqiu Xiu; Qi Zhang; Jianjing Hou; Jia Wang; Jiong Wu
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.